Park Sonya Youngju, Yoon Hyukjin, Han Eun Ji, Yoo Ie Ryung
Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Diagnostics (Basel). 2023 Oct 2;13(19):3112. doi: 10.3390/diagnostics13193112.
The development of therapeutic agents targeting products of epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) rearrangements has improved survival in patients with non-small-cell lung cancer. EGFR and ALK mutations are generally regarded as mutually exclusive, and the presence of one in lieu of another influences the response to targeted therapy. We herein present an interesting case following the course of progression of a patient with synchronous lung cancers with a discordant mutation profile. The importance of this modality in the follow-up of lung cancer patients is illustrated, and the therapeutic implications of coexisting oncogenic drivers are briefly discussed.
针对表皮生长因子受体（EGFR）基因突变产物和间变性淋巴瘤激酶（ALK）重排的治疗药物的研发，已提高了非小细胞肺癌患者的生存率。EGFR和ALK突变通常被认为是相互排斥的，其中一种突变的存在会影响对靶向治疗的反应。在此，我们报告一例有趣的病例，该病例为一名患有同步性肺癌且突变谱不一致的患者的病程进展。本文阐述了这种模式在肺癌患者随访中的重要性，并简要讨论了共存致癌驱动因素的治疗意义。
